COG AALL1731
In children with average-risk leukaemia, adding blinatumomab pushed three-year disease-free survival from 88% to 96%, one of the largest gains in decades.
1,440 randomised children with standard-risk average or high subsets. 3-year DFS 96.0% vs 87.9% (HR 0.39, 95% CI 0.24-0.64); randomisation stopped early for efficacy. NEJM 2024. Led to FDA approval of blinatumomab in the consolidation phase for CD19+ Ph-negative B-ALL in children (June 2024) and is being adopted as the new paediatric standard.
- 96 vs 87.9 out of 100 alive without the cancer coming back at 3 years with Blinatumomab + chemotherapy compared with Chemotherapy; 8.1 more per 100.
- Roughly one extra person helped for every 12 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 61 percent lower chance of the event at any given time (hazard ratio 0.39, likely range 0.24 to 0.64).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Newly diagnosed standard-risk B-ALL in children: two cycles of blinatumomab added to chemotherapy vs chemotherapy alone. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,440 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease-free survival at 3 yearsprimary | Blinatumomab + chemotherapy | 722 | 96% | 0.39 (0.24–0.64) | <0.001 | link |
| Chemotherapy | 718 | 87.9% |
Pages like this
not linked directly; found by shared links- TrialTOWER
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
- TrialECOG-ACRIN E1910
Shares Blinatumomab added to frontline chemotherapy, Blinatumomab, CD3, CD19.
- Key paperECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission
Shares Blinatumomab added to frontline chemotherapy, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, CD3.
- PersonMark R. Litzow
Shares Blinatumomab, CD3, CD19, Acute lymphoblastic leukaemia.
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Children's Oncology Group (COG), Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- TrialInterfant-06
Shares Blinatumomab, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- IdeaEscrow a share of adult revenue until the paediatric study is done
Shares Children's Oncology Group (COG), Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- InstitutionChildren's Hospital of Philadelphia
Shares Children's Oncology Group (COG), CD19, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.